Evidence map›Paper›PMID 42645380›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Eli Zolotov, Reema Mody, Kimberley Doucette, Aimee Chappell, Chantal Accolatse-Mati, Harsh Parmar, James Di Palma-Grisi, Noa Biran, Pooja Phull, Joseph Franz and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eli ZolotovDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.ORCID 0000-0003-3022-2547
Reema ModyDepartment of Medicine, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Kimberley DoucetteDepartment of Hematology and Medical Oncology, Medstar Georgetown University Hospital, Washington, DC 20007, USA.
Aimee ChappellDepartment of Hematology and Medical Oncology, Medstar Georgetown University Hospital, Washington, DC 20007, USA.
Chantal Accolatse-MatiDepartment of Hematology and Medical Oncology, Medstar Georgetown University Hospital, Washington, DC 20007, USA.ORCID 0000-0003-4895-5327
Harsh ParmarDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.
James Di Palma-GrisiDepartment of Medicine, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Noa BiranDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Pooja PhullDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Joseph FranzDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.
David S SiegelDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.ORCID 0000-0002-3604-2574
David H VesoleDivision of Myeloma, John Theurer Cancer Center (JTCC), Hackensack University Medical Center, Hackensack, NJ 07601, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) patients with end-stage renal disease (ESRD) requiring hemodialysis (HD), who are disproportionately Black, have been excluded from all pivotal trials of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, leaving a critical evidence gap in a population. We conducted a multicenter retrospective analysis of all MM patients who received CAR-T therapy while on HD at two U.S. centers between June 2021 and December 2025. Of 284 CAR-T recipients, 8 (2.8%) were HD-dependent. Median age was 63 years; 62.5% were female and 75% were Black; patients had received a median of 6 prior lines. Five received ciltacabtagene autoleucel and three received idecabtagene vicleucel; lymphodepletion was bendamustine (

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveKidney Failure, ChronicMultiple MyelomaRenal DialysisAgedFemaleHumansMaleMiddle AgedRetrospective StudiesB-Cell Maturation AntigenBCMAbendamustineCAR-Tend-stage renal diseasehealth disparitieshemodialysislymphodepletionmultiple myelomareal-world evidence

Identifiers

PMID42645380
PMCPMC13510913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.